部分中文前列地尔处方资料（仅供参考）
商品名：Alprostadil Syringe
英文名：Alprostadil
中文名：前列地尔预充注射器
生产商：东和制药
药品简介
前列地尔（Alprostadil）是一种扩血管药物，可抑制血小板凝集，在临床上广泛使用改善微循环。治疗慢性动脉闭塞症（血栓闭塞性脉管炎、闭塞性动脉硬化症等）引起的四肢溃疡及微小血管循环障碍引起的四肢静息疼痛，改善心脑血管微循环障碍。脏器移植术后抗栓治疗，也用以抑制移植后血管内的血栓形成。 
アルプロスタジル注10μgシリンジ「トーワ」
治疗类别名称
前列腺素E1製剤
批准日期：
欧文商標名
ALPROSTADIL INJECTION 5μg SYRINGE "TOWA
ALPROSTADIL INJECTION 10μg SYRINGE "TOWA
一般名：アルプロスタジル（Alprostadil）
化学名：7-{(1R,2R,3R)-3-Hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl}heptanoic acid
分子式：C20H34O5
分子量：354.48
構造式：
性　状：
它是一种白色晶体或结晶粉末。乙醇（99.5），或易溶于四氢呋喃和微溶于乙腈中，几乎不溶于水。
熔点：
114〜118℃
药效药理
1.药效学试验
(1) 对血小板聚集的作用
对于前列地尔注10μg的注射器“TOWA”和标准制剂，采用全血的血小板凝集能力测定装置的措施在人全血中的血小板聚集，需要一个胶原浓度以诱导50％的聚集压力作为比较的结果，显示了血小板凝集抑制作用，这两种药物的效果被确定生物等效。
(2) 颈动脉血流和血压的影响
前列地尔注10μg的注射器“TOWA”和标准配方（0.1微克/公斤）从在正常犬右股静脉（1组26只）在麻醉下，最大血流量变化和平均血压在颈总动脉给药你在哪里相比下降的最大量，这两种药物还显示出增加和降血压效果的血流量，分别的动作被判断为生物等效。
(3) 外周血流量和血压的影响
前列地尔注10μg的注射器“TOWA”和标准配方（3微克/公斤）从尾静脉施用菌素（STZ）诱导的糖尿病大鼠（第1组15只动物），下后腿足垫的最大血流量变化和平均血压的最大下降量进行比较研究的结果，这两种药物还显示出增加和降血压效果的血流量的作用的，分别被判断为生物等效。
2. 作用机序
它作用于前列腺素类受体在血管平滑肌，改善外周循环障碍表明通过增加细胞内cAMP一个血管扩张活性。此外，它还具有血小板聚集抑制作用。
适应症
・改善慢性动脉闭塞（汉堡病、动脉硬化闭塞症）的肢体溃疡和静息痛
・改善以下疾病的皮肤溃疡
进行性系统性硬化
系统性红斑狼疮
・改善糖尿病皮肤溃疡
・改善振动病中与末梢血液循环障碍相关的主观症状，以及末梢循环、神经和运动功能障碍的恢复
・动脉导管依赖性先天性心脏病的爱国动脉导管
用法用量
・用于慢性动脉闭塞（汉堡病、闭塞性动脉硬化）、进行性系统性硬化症、系统性红斑狼疮、糖尿病、振动病
一般而言，对于成人，每天一次给药 1至2毫升（前列地尔5至10 微克），或与输液混合后缓慢静脉内或静脉内输注。 可根据患者的症状调整剂量。
・动脉导管依赖型先天性心脏病
与输液混合，开始时以5 ng/kg/min持续输注前列地尔，然后根据症状调整剂量至最小有效剂量。
包装规格
注射器：5微克“TOWA”：1毫升×5注射器

注射器：10微克“TOWA”：2毫升×5注射器
生产商：
东和制药有限公司有限公司
注：以上中文处方资料不够完整，使用者以原处方资料为准。
完整说明书附件：
https://www.info.pmda.go.jp/go/pack/2190406G2070_1_03/
---------------------------------------------
ALPROSTADIL INJECTION SYRINGE（Alprostadil）
ALPROSTADIL INJECTION 5mcg SYRINGE "TOWA" [arterial duct-dependent congenital heart disease]（アルプロスタジル注5μgシリンジ「トーワ」［動脈管依存性先天性心疾患］）
Brand name : ALPROSTADIL INJECTION 5mcg SYRINGE "TOWA" [arterial duct-dependent congenital heart disease]
　Active ingredient: Alprostadil
　Dosage form: injection
　Print on wrapping:
ALPROSTADIL INJECTION 5mcg SYRINGE "TOWA" [chronic arterial obstruction, progressive systemic sclerosis, systemic erythematosus, diabetes mellitus, vibration disease]（アルプロスタジル注5μgシリンジ「トーワ」［慢性動脈閉塞症、進行性全身性硬化症、全身性エリテマトーデス、糖尿病、振動病］）
Brand name : ALPROSTADIL INJECTION 5mcg SYRINGE "TOWA" [chronic arterial obstruction, progressive systemic sclerosis, systemic erythematosus, diabetes mellitus, vibration disease]
　Active ingredient: Alprostadil
　Dosage form: injection
　Print on wrapping:
ALPROSTADIL INJECTION 5mcg SYRINGE "TOWA" [superior mesenteric arterial portography]（アルプロスタジル注5μgシリンジ「トーワ」［経上腸間膜動脈性門脈造影］）
Brand name : ALPROSTADIL INJECTION 5mcg SYRINGE "TOWA" [superior mesenteric arterial portography]
　Active ingredient: Alprostadil
　Dosage form: injection
　Print on wrapping:
Effects of this medicine
This medicine dilates the vessel to intensify the effect of contrast dye during portography.
It is usually used to improve imaging ability on superior mesenteric arterial portography.
Before using this medicine, be sure to tell your doctor and pharmacist
If you have previously experienced any allergic reactions(itch, rash, etc.) to any medicines.
If you have heart disease, bleeding(black stool, vomiting of blood), glaucoma, elevated eye pressure, interstitial pneumonia, renal disease, bleeding tendency, esophageal varices.
If you have stomach ulcer or have a history of it.
If you are pregnant, breastfeeding or possibly pregnant.
If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.)
Dosing schedule (How to take this medicine)
Your dosing schedule prescribed by your doctor is<<to be written by a healthcare professional>>
In general, inject into superior mesenteric artery 30 seconds before contrast dye injection.
Precautions while taking this medicin
Possible adverse reactions to this medicine
The most commonly reported adverse reactions include nausea, stomachache, vomiting, diarrhea, abdominal bloating/discomfort, blood pressure reduction, vasculitis, hot flush in face, feeling of chest tightness, chest pain, elevated blood pressure, asthma, fever, headache, rash, itch, exacerbation of renal failure (swelling, decreased urine output, headache), vascular pain/redness at the injection site, bleeding (nose/eyeground/conjunctiva/subcutaneous bleeding, bloody urine) or feeling of warmth. If any of these symptoms occur, consult with your doctor or pharmacist.
The symptoms described below are rarely seen as initial symptoms of the adverse reactions indicated in brackets. If any of these symptoms occur, stop taking this medicine and see your doctor immediately.
hives, swelling of larynx, respiratory distress[shock, anaphylactoid symptoms]
loss of conciousness[loss of conciousness]
palpitation, chest tightness, respiratory distress[heart failure, pulmonary edema]
fever, dry cough, respiratory distress[interstitial pneumonia]
chest pain, feeling of chest tightness[myocardial infarction]
The above symptoms do not describe allthe adverse reactions to this medicine. Consult with your doctor or pharmacist if you notice any symptoms of concern other than those listed above.
TOWA PHARMACEUTICAL CO., LTD. Injection
Published: 12/2012
The information on this sheet is based on approvals granted by the Japanese regulatory authority. Approval details may vary by country. Medicines have adverse reactions (risks) as well as efficacies (benefits). It is important to minimize adverse reactions and maximize efficacy. To obtain a better therapeutic response, patients should understand their medication and cooperate with the treatment.